Related Experiment Video

Updated: May 14, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Antidiabetic actions of an estrogen receptor β selective agonist

Paloma Alonso-Magdalena1, Ana B Ropero, Marta García-Arévalo

  • 1Institute of Bioengineering and Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders, Miguel Hernandez University of Elche, Alicante, Spain. Alonso-Magdalena, palonso@umh.es

Diabetes
|January 26, 2013
PubMed

Insights

Estrogen receptor beta (ERβ) agonists, like WAY200070, enhance insulin secretion and improve glucose control in diabetic models. These findings suggest ERβ agonists are promising new therapeutic targets for diabetes treatment.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Estrogen receptor beta (ERβ) plays a role in pancreatic endocrine function.
  • ERβ agonists are being investigated for potential therapeutic applications.

Purpose of the Study:

  • To evaluate the role of the ERβ selective agonist WAY200070 as an insulinotropic molecule.
  • To assess the antidiabetic actions of WAY200070.

Main Methods:

  • In vitro studies using mouse and human islets to assess glucose-stimulated insulin secretion.
  • In vivo studies in streptozotocin-nicotinamide-induced diabetic mice and db/db mice to evaluate antidiabetic effects.
  • Assessment of plasma insulin levels, glucose tolerance, insulin sensitivity, and pancreatic beta-cell mass.

Main Results:

  • WAY200070 significantly enhanced glucose-stimulated insulin secretion in both mouse and human islets.
  • In vivo administration of WAY200070 improved glucose tolerance, increased plasma insulin levels, and enhanced beta-cell mass in diabetic models.
  • Two-week treatment with WAY200070 improved glucose and insulin sensitivity and restored first-phase insulin secretion in db/db mice.

Conclusions:

  • ERβ agonists, exemplified by WAY200070, demonstrate significant insulinotropic and antidiabetic effects.
  • WAY200070 promotes beta-cell regeneration and improves overall glucose homeostasis.
  • ERβ agonists represent a novel therapeutic target for managing diabetes.

More Related Videos

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay06:07

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay

Published on: June 7, 2020

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...